Follow
Lloyd Wei Tat Tang
Title
Cited by
Cited by
Year
Infigratinib is a Reversible Inhibitor and Mechanism-based Inactivator of Cytochrome P450 3A4
LWT Tang, JW Teng, RK Verma, SK Koh, L Zhou, ML Go, H Fan, ...
Drug Metabolism and Disposition 49 (9), 856-868, 2021
172021
Mechanism-based inactivation of cytochrome P450 3A4 by benzbromarone
LWT Tang, RK Verma, H Fan, ECY Chan
Molecular Pharmacology 99 (4), 266-276, 2021
142021
Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A
LWT Tang, W Wei, RK Verma, SK Koh, L Zhou, H Fan, ECY Chan
Drug Metabolism and Disposition 50 (5), 529-540, 2022
122022
Metabolic activation of the acrylamide michael acceptor warhead in futibatinib to an epoxide intermediate engenders covalent inactivation of CYP3A
LWT Tang, J Fu, SK Koh, G Wu, L Zhou, ECY Chan
Drug Metabolism and Disposition 50 (7), 931-941, 2022
112022
Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib
LWT Tang, JW Teng, SK Koh, L Zhou, ML Go, ECY Chan
Chemical Research in Toxicology 34 (7), 1800-1813, 2021
112021
Identification of infigratinib as a potent reversible inhibitor and mechanism-based inactivator of CYP2J2: nascent evidence for a potential in vivo metabolic drug-drug …
LWT Tang, G Wu, ECY Chan
Journal of Pharmacology and Experimental Therapeutics 382 (2), 123-134, 2022
92022
Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5
LWT Tang, RK Verma, RP Yong, X Li, L Wang, Q Lin, H Fan, ECY Chan
Molecular Pharmacology 100 (3), 224-236, 2021
82021
Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents
HL Tan, LWT Tang, SY Chin, ECY Chan
Drug Metabolism and Pharmacokinetics 38, 100390, 2021
82021
Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology
JWH Leow, LWT Tang, ECY Chan
Advances in Pharmacology 95, 131-176, 2022
72022
Tissue-Specific microRNA expression profiling to derive novel biomarkers for the diagnosis and subtyping of small B-Cell lymphomas
SSS Hue, Y Jin, H Cheng, MS Bin Masroni, LWT Tang, YH Ho, DBL Ong, ...
Cancers 15 (2), 453, 2023
42023
Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical …
LWT Tang, ECY Chan
Biochemical Pharmacology 206, 115336, 2022
42022
Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes …
LWT Tang, ECY Chan
Journal of Pharmaceutical and Biomedical Analysis 214, 114731, 2022
42022
Rational deuteration of dronedarone attenuates its toxicity in human hepatic HepG2 cells
LWT Tang, RYR Lim, G Venkatesan, ECY Chan
Toxicology Research 11 (2), 311-324, 2022
42022
Combination Bacillus Calmette-Guérin and indoleamine 2, 3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer
SH Lee, R Mahendran, SM Tham, TP Thamboo, DYQ Kioh, LWT Tang, ...
BJU International 126 (5), 554-556, 2020
22020
Febuxostat and its Major Acyl Glucuronide Metabolite are Potent Inhibitors of Organic Anion Transporter 3: Implications for Drug‐Drug Interactions with Rivaroxaban
LWT Tang, TWH Cheong, ECY Chan
Biopharmaceutics & Drug Disposition, 2022
12022
Characterization and Applications of Permeabilized Hepatocytes in Drug Discovery
S Zhang, CC Orozco, LWT Tang, J Racich, AA Carlo, G Chang, D Tess, ...
The AAPS Journal 26 (3), 1-11, 2024
2024
Novel Multiplexed High Throughput Screening of Selective Inhibitors for Drug-Metabolizing Enzymes Using Human Hepatocytes
J Liu, D Vernikovskaya, G Bora, A Carlo, W Burchett, S Jordan, LWT Tang, ...
The AAPS Journal 26 (3), 1-13, 2024
2024
Probe Substrate Dependencies in CYP3A4 Allosteric Inhibition: A Novel Molecular Mechanism Involving F–F′ Loop Perturbations
W Wei, LWT Tang, RK Verma, H Fan, ECY Chan
Journal of Chemical Information and Modeling 64 (6), 2058-2067, 2024
2024
Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates
J Chen, LWT Tang, S Jordan, M Harrison, GM Gualtieri, E DaSilva, ...
The AAPS Journal 26 (2), 26, 2024
2024
Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes
LWT Tang, E DaSilva, K Lapham, RS Obach
Drug Metabolism and Disposition, 2024
2024
The system can't perform the operation now. Try again later.
Articles 1–20